Alpha-blockers effectively target this sympathetic dysregulation, potentially explaining their enhanced protective effect in patients with diabetes by reducing nocturia-related fall risk while simultaneously improving peripheral insulin sensitivity and attenuating orthostatic hypotension [34]. Here, INS is linked to diabetes mellitus.